Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) -- Ignore unavailable to you. Want to Upgrade?

To: I_Banker who wrote (336)	1/9/2005 10:05:06 AM
From: idahoranch1	Respond to of 371

Banker, it was not a double blind nor a head to head. They simply infused CD22 and CD20 (Rituxan) and treated NHL patients. No one I know can understand what the heck they were doing. The data is almost worthless from that trial. It really is as if they liscensed E-mab in 2000 and pretty much pigeonholed it, for whatever reason. The sponsering company picks up the tab for the drugs in the trials, so they aren't selling anything. The double blind, head to head trials are expensive.